Pharmacogenomic Study on PKD/PKC of Dabigatran Etexilate and Rivaroxaban

New Oral Anticoagulant Drugs Dabigatran Etexilate and Rivaroxaban: Influence of Genetic Factors in Healthy Volunteers

The study will address the impact of genetical variation of a protein involved in the intestinal absorption of two new anticoagulants : Dabigatran etexilate and Rivaroxaban.

The study will address the impact of genetical variation of a protein involved in the intestinal absorption of two new anticoagulants : Dabigatran etexilate and Rivaroxaban.

Inclusion Criteria:

• Healthy participants
• Aged between 18-35 years inclusive
• Male
• Caucasian
• Body mass index (BMI) between 18 and 27 kg per m² inclusive.